|
1
|
Ellis LM, Rosen L and Gordon MS: Overview
of anti-VEGF therapy and angiogenesis. Part 1 Angiogenesis
inhibition in solid tumor malignancies. Clin Adv Hematol Oncol. 4
(Suppl):1–10. 2006.PubMed/NCBI
|
|
2
|
Hurwitz HI, Fehrenbacher L, Hainsworth JD,
Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and
Kabbinavar F: Bevacizumab in combination with fluorouracil and
leucovorin: An active regimen for first-line metastatic colorectal
cancer. J Clin Oncol. 23:3502–3508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Connolly DT: Vascular permeability factor:
A unique regulator of blood vessel function. J Cell Biochem.
47:219–223. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Howlader N, Noone AM, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2009 (vintage 2009
populations). National Cancer Institute; Bethesda, MD: 2012
|
|
5
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dores GM, Devesa SS, Curtis RE, Linet MS
and Morton LM: Acute leukemia incidence and patient survival among
children and adults in the United States, 2001–2007. Blood.
119:34–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moorman AV, Chilton L, Wilkinson J, Ensor
HM, Bown N and Proctor SJ: A population-based cytogenetic study of
adults with acute lymphoblastic leukemia. Blood. 115:206–214. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patel JP, Gönen M, Figueroa ME, Fernandez
H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S,
Aminova O, et al: Prognostic relevance of integrated genetic
profiling in acute myeloid leukemia. N Engl J Med. 366:1079–1089.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghosh K, Swaminathan S, Madkaikar M, Gupta
M, Kerketta L and Vundinti B: FLT3 and NPM1 mutations in a cohort
of AML patients and detection of a novel mutation in tyrosine
kinase domain of FLT3 gene from Western India. Ann Hematol.
91:1703–1712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hung CH, Yang SN, Kuo PL, Chu YT, Chang
HW, Wei WJ, Huang SK and Jong YJ: Modulation of cytokine expression
in human myeloid dendritic cells by environmental
endocrine-disrupting chemicals involves epigenetic regulation.
Environ Health Perspect. 118:67–72. 2010.PubMed/NCBI
|
|
11
|
Todorovic M, Radisavljevic Z, Balint B,
Andjelic B, Todorovic V, Jovanovic MP and Mihaljevic B: Increased
angiogenesis-associated poor outcome in acute lymphoblastic
leukemia: A single center study. Appl Immunohistochem Mol Morphol.
20:488–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Connolly DT, Heuvelman DM, Nelson R,
Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM and
Feder J: Tumor vascular permeability factor stimulates endothelial
cell growth and angiogenesis. J Clin Invest. 84:1470–1478. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hahn D, Simak R, Steiner GE, Handisurya A,
Susani M and Marberger M: Expression of the VEGF-receptor Flt-1 in
benign, premalignant and malignant prostate tissues. J Urol.
164:506–510. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fontanella C, Ongaro E, Bolzonello S,
Guardascione M, Fasola G and Aprile G: Clinical advances in the
development of novel VEGFR2 inhibitors. Ann Transl Med.
2:1232014.PubMed/NCBI
|
|
15
|
Sahni A and Francis CW: Vascular
endothelial growth factor binds to fibrinogen and fibrin and
stimulates endothelial cell proliferation. Blood. 96:3772–3778.
2000.PubMed/NCBI
|
|
16
|
Keyhani A, Jendiroba DB and Freireich EJ:
Angiogenesis and leukemia. Leuk Res. 25:639–645. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shalaby F, Rossant J, Yamaguchi TP,
Gertsenstein M, Wu XF, Breitman ML and Schuh AC: Failure of
blood-island formation and vasculogenesis in Flk-1-deficient mice.
Nature. 376:62–66. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song GL and Han ZC: Malignant hematologic
disease and angiogenesis. Zhonghua Xue Ye Xue Za Zhi. 23:217–219.
2002.(In Chinese).
|
|
19
|
Kampen KR, Ter Elst A and de Bont ES:
Vascular endothelial growth factor signaling in acute myeloid
leukemia. Cell Mol Life Sci. 70:1307–1317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kvasnicka HM and Thiele J: Bone marrow
angiogenesis: Methods of quantification and changes evolving in
chronic myeloproliferative disorders. Histol Histopathol.
19:1245–1260. 2004.PubMed/NCBI
|
|
21
|
Kuzu I, Beksac M, Arat M, Celebi H, Elhan
AH and Erekul S: Bone marrow microvessel density (MVD) in adult
acute myeloid leukemia (AML): Therapy induced changes and effects
on survival. Leuk Lymphoma. 45:1185–1190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Du W, Hattori Y, Hashiguchi A, Kondoh K,
Hozumi N, Ikeda Y, Sakamoto M, Hata J and Yamada T: Tumor
angiogenesis in the bone marrow of multiple myeloma patients and
its alteration by thalidomide treatment. Pathol Int. 54:285–294.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Perez-Atayde AR, Sallan SE, Tedrow U,
Connors S, Allred E and Folkman J: Spectrum of tumor angiogenesis
in the bone marrow of children with acute lymphoblastic leukemia.
Am J Pathol. 150:815–821. 1997.PubMed/NCBI
|
|
24
|
Padró T, Ruiz S, Bieker R, Bürger H,
Steins M, Kienast J, Büchner T, Berdel WE and Mesters RM: Increased
angiogenesis in the bone marrow of patients with acute myeloid
leukemia. Blood. 95:2637–2644. 2000.PubMed/NCBI
|
|
25
|
Harris NL, Jaffe ES, Diebold J, Flandrin
G, et al: World Health Organization classification of neoplastic
diseases of the hematopoietic and lymphoid tissues: Report of the
Clinical Advisory Committee meeting-Airlie House, Virginia,
November 1997. J Clin Oncol. 17:3835–3849. 1999.PubMed/NCBI
|
|
26
|
Mangi MH and Newland AC: Angiogenesis and
angiogenic mediators in hematological malignancies. Br J Hematol.
111:43–51. 2000. View Article : Google Scholar
|
|
27
|
Swerdlow SH, Campo E, Harris NL, et al:
WHO Classification of Tumors of Haematopoietic and Lymphoid
Tissues. 4th. IARC Press; Lyon, France: 2008
|
|
28
|
Kini AR, Peterson LA, Tallman MS and
Lingen MW: Angiogenesis in acute promyelocytic leukemia: Induction
by vascular endothelial growth factor and inhibition by all-trans
retinoic acid. Blood. 97:3919–3924. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vacca A, Ribatti D, Roncali L, Ranieri G,
Serio G, Silvestris F and Dammacco F: Bone marrow angiogenesis
andprogression in multiple myeloma. Br J Haematol. 87:503–508.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weidner N: Current pathologic methods for
measuring intratumoral microvessel density within breast carcinoma
and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
List AF, Glinsmann-Gibson B, Stadheim C,
Meuillet EJ, Bellamy W and Powis G: Vascular endothelial growth
factor receptor-1 and receptor-2 initiate a phosphatidylinositide
3-kinase-dependent clonogenic response in acute myeloid leukemia
cells. Exp Hematol. 32:526–535. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kuo CJ, Farnebo F, Yu EY, Christofferson
R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn
E, et al: Comparative evalution of the antitumor activity of
antiangiogenic proteins delivered by gene transfer. Proc Natl Acad
Sci USA. 98:4605–4610. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kendall RL, Wang G and Thomas KA:
Identification of a natural soluble form of the vascular
endothelial growth factor receptor, FLT-1 and its
heterodimerization with KDR. Biochem Biophys Res Commun.
226:324–328. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin P, Sankar S, Shan S, Dewhirst MW,
Polverini PJ, Quinn TQ and Peters KG: Inhibition of tumor growth by
targeting tumor endothelium using a soluble vascular endothelial
growth factor receptor. Cell Growth Differ. 9:49–58.
1998.PubMed/NCBI
|
|
35
|
Haouas H: Angiogenesis and acute myeloid
leukemia. Hematology. 19:311–323. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Bont ES, Fidler V, Meeuwsen T, Scherpen
F, Hählen K and Kamps WA: Vascular endothelial growth factor
secretion is an independent prognostic factor for relapse-free
survival in pediatric acute myeloid leukemia patients. Clin Cancer
Res. 8:2856–2861. 2002.PubMed/NCBI
|
|
37
|
Dias S, Hattori K, Heissig B, Zhu Z, Wu Y,
Witte L, Hicklin DJ, Tateno M, Bohlen P, et al: Inhibition of both
paracrine and autocrine VEGF/VEGFR-2 signaling pathways is
essential to induce long-term remission of xenotransplanted human
leukemias. Proc Natl Acad Sci USA. 98:10857–10862. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rodriguez-Ariza A, Lopez-Pedrera C, Aranda
E and Barbarroja N: VEGF targeted therapy in acute myeloid
leukemia. Crit Rev Oncol Hematol. 80:241–256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang ZN: Diagnosis and treatment criteria
of hematopathy. 2nd. Beijing: Science Press, Beijing; 1998
|
|
40
|
Song G, Li Y and Jiang G: Role of
VEGF/VEGFR in the pathogenesis of leukemias and as treatment
targets (Review). Oncol Rep. 28:1935–1944. 2012.PubMed/NCBI
|
